AI assistant
Sending…
Altimmune, Inc. — Director's Dealing 2019
Jan 4, 2019
33207_dirs_2019-01-04_667dcaf8-19fe-4cba-9571-a4276ee38cd3.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Altimmune, Inc. (ALT)
CIK: 0001326190
Period of Report: 2019-01-02
Reporting Person: Brown William Michael (Acting Chief Financial Officer)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2019-01-02 | Stock Options (option to buy) | $2.60 | A | 30000 | Acquired | 2024-01-02 | Common Stock, par value $0.0001 (30000) | Direct |
Footnotes
F1: The option becomes vested and exercisable upon the filing of the Issuer's annual statement on Form 10-K with respect to the fiscal year ended December 31, 2018, generally subject to the reporting person's continued service through the vesting date.
More from Altimmune, Inc.
Regulatory Filings
2026
May 13
Regulatory Filings
2026
May 13
Regulatory Filings
2026
Apr 22
Regulatory Filings
2026
Apr 16
Major Shareholding Notification
2026
Mar 26
Annual Report
2026
Mar 17
Proxy Solicitation & Information Statement
2026
Mar 17
Director's Dealing
2026
Feb 27
Director's Dealing
2026
Feb 27
Regulatory Filings
2026
Feb 6